A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Tafluprost (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacokinetics
- Sponsors Santen Oy
- 09 Oct 2017 Status changed from recruiting to completed.
- 25 Jul 2017 This study has been completed in Poland (end date:2017-06-05), according to European Clinical Trials Database.
- 14 Jul 2017 This study has been completed in Hungary as per European Clinical Trials Database.